Wall Street analyst estimates for Sutro Biopharma, Inc. (STRO): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of innovative therapeutic products. Its primary objective is to create protein-based treatments for challenging conditions like cancer and autoimmune disorders. The company achieves this through its proprietary XpressCF+ platform, a unique technology that integrates cell-free protein synthesis with precise, site-specific drug conjugation.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-05 | $-1.66 | ||
| 2026-08-12 | $-2.33 | $-2.19 | -6.4% |
| 2026-05-14 | $-2.94 | $-2.32 | -26.7% |
| 2026-03-23 | $-5.29 | $-8.16 | +35.2% |
| 2025-11-06 | $-6.70 | $-3.94 | -69.9% |
| 2025-08-07 | $-1.40 | $-3.82 | +63.4% |
| 2025-05-08 | $-9.10 | $-6.30 | -44.4% |
| 2025-03-13 | $-8.90 | $-8.30 | -7.2% |
Valuation Ratios
| Price / Book | -2.10 |
| EV / EBITDA | -0.89 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $59.7M | $51.7M | $38.4M | $42.7M | $42.7M | $61.9M | $67.8M | $153.7M | $62.0M | $102.5M |
| Cost of Revenue | $43.5M | $51.9M | $54.3M | 0 | $77.0M | $9.8M | $8.3M | $6.8M | $7.2M | $7.3M |
| Gross Profit | $16.2M | -$156000 | -$15.8M | $42.7M | -$34.2M | $52.1M | $59.5M | $146.9M | $54.8M | $95.2M |
| Research & Development | $43.5M | $54.6M | $54.3M | $65.6M | $77.0M | $104.4M | $137.2M | $180.4M | $252.0M | $166.4M |
| Selling, General & Admin | $14.8M | $16.4M | $21.4M | $32.6M | $36.8M | $56.0M | $59.5M | $62.6M | $48.5M | $41.0M |
| Operating Expenses | $58.4M | $71.0M | $75.6M | $98.2M | $36.8M | $150.6M | $188.4M | $236.2M | $293.3M | $200.1M |
| Operating Income | $1.4M | -$19.3M | -$37.2M | -$55.5M | -$71.1M | -$98.5M | -$128.9M | -$89.3M | -$238.5M | -$105.0M |
| EBITDA | $7.4M | -$14.1M | -$32.8M | -$46.6M | -$23.8M | -$97.6M | -$105.1M | -$67.9M | -$180.5M | -$145.6M |
| Interest Expense | 0 | $689000 | $1.6M | $4.3M | $4.0M | $3.1M | $3.3M | $23.8M | $31.1M | $38.2M |
| Pre-tax Income | $1.7M | -$19.7M | -$35.3M | -$55.7M | -$32.1M | -$105.5M | -$116.7M | -$88.6M | -$225.1M | -$191.2M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | $2.5M | $18.2M | $2.4M | -$93000 |
| Net Income | $1.7M | -$19.7M | -$35.3M | -$55.7M | -$32.1M | -$105.5M | -$119.2M | -$106.8M | -$227.5M | -$191.1M |
| EPS | $38.60 | $-28.10 | $-15.50 | $-24.30 | $-9.90 | $-22.90 | $-23.50 | $-17.80 | $-29.60 | $-22.49 |
| EPS (Diluted) | $38.60 | $-28.10 | $-15.40 | $-24.30 | $-9.90 | $-22.90 | $-23.50 | $-17.80 | $-29.60 | $-22.49 |
| Shares Outstanding (Diluted) | $44120 | $699739 | $2.3M | $2.3M | $3.3M | $4.6M | $5.1M | $6.0M | $7.7M | $8.5M |
Price
| Price | $15.60 |
| Market Cap | $151M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ADVM · ARTV · CNTB · DTIL · GUTS · IFRX · KLRS
Explore sector: Healthcare · Biotechnology
More sections of STRO: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks